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RNA interference (RNAi) is a powerful tool for studying gene function owing to the ease with which it can selectively silence genes
of interest, and it has also attracted attention because of its potential for therapeutic applications. Chemically synthesized small
interferingRNAs(siRNAs)andDNAvector-basedshorthairpinRNAs(shRNAs)arenowwidelyusedasRNAitriggers.Incontrast
to expressed shRNAs, the use of synthetic shRNAs is limited. Here we designed shRNAs modeled on a precursor microRNA (pre-
miRNA) and evaluated their biological activity. We demonstrated that chemically synthetic pre-miRNA-based shRNAs have more
potent RNAi activity than their corresponding siRNAs and found that their antisense strands are more eﬃciently incorporated
into the RNA-induced silencing complex. Although greater oﬀ-target eﬀects and interferon responses were induced by shRNAs
than by their corresponding siRNAs, these eﬀects could be overcome by simply using a lower concentration or by optimizing and
chemically modifying shRNAs similar to synthetic siRNAs. These are challenges for the future.
1.Introduction
RNA interference (RNAi) is an evolutionarily conserved,
gene-silencing mechanism that is triggered by double-
stranded RNA (dsRNA). Two types of small RNA—namely,
small interfering RNA (siRNA) and microRNA (miRNA)—
are central players in RNAi. Both siRNAs and miRNAs
regulate gene expression by annealing to mRNA sequence
elements that are fully or partially complementary [1, 2].
Since transfected synthetic siRNAs were shown to induce
RNAi in mammalian cells [3], they have been widely used
to decipher gene function through suppression of gene
expression, and they have also attracted attention because of
their potential for therapeutic applications [4, 5]. miRNAs
are a phylogenetically conserved family of endogenous
small RNAs that play important roles in a wide variety of
biological functions, including cell diﬀerentiation, tumor
genesis, apoptosis, and metabolism [1, 2, 6, 7].
miRNAs are initially generated as long primary tran-
scripts (pri-miRNA) that are processed in the nucleus by
the enzyme complexes Drosha and DiGeorge Critical Region
8 (DGCR8) to a 70–90nt stem-loop structure called pre-
miRNA. The pre-miRNA is then exported to the cytoplasm.
There, the exported pre-miRNA or exogenous dsRNA is
cleaved by the enzyme Dicer into a ∼22-nucleotide (nt)
duplex known as miRNA or siRNA, respectively. The duplex
is then incorporated into the RNA-induced silencing com-
plex (RISC). After removing one strand called the passenger
strand, the remaining strand, called the guide strand, in the
RISC guides the silencing complex to target mRNAs. Thus,
downstream of their initial processing, siRNAs and miRNAs
share the same cellular machinery [1, 2].
Understanding the mechanism of the RNAi pathway has
led to the development of alternative approaches of RNAi.
S e v e r a lg r o u p sh a v ed e v e l o p e da r t i ﬁ c i a lm i R N A si nt h e
form of short-hairpin structures, called shRNAs, instead of
siRNAs[8,9].DNAvector-basedshRNAsarewidelyused.By
contrast, the use of synthetic shRNAs is very limited [10–12],
although synthetic shRNAs can easily incorporate chemical
modiﬁcations to improve their stability and biological activ-
ity, similar to synthetic siRNAs. Probably, this limited use is
because the chemical synthesis of long RNA oligonucleotides
is generally diﬃcult, consequently leading to high cost and
low yield. Unlike DNA oligonucleotides, synthesis of RNA2 Journal of Nucleic Acids
is less eﬃcient owing to problems caused by the presence
of the 2 -hydroxyl group of ribose, which requires selective
protection during oligonucleotide assembly. Recently, a
new protecting group, 2-cyanoethoxymetyhyl (CEM), has
been developed [13]. By improving capping and coupling
conditions, the authors succeeded in synthesizing a 110mer
pre-miRNA candidate and conﬁrmed its biological activity
[14]. Thus, synthetic long oligonucleotides are becoming a
reality at a reasonable cost. In this study, we have designed
shRNAs modeled on pri-miRNA and have evaluated their
biological activity.
2.MaterialsandMethods
2.1. Synthetic RNA Oligonucleotides. The siRNA sequence
targeting LMNA (GenBank accession number: NM 170707)
was from position 600–620 relative to the start codon. The
shRNAs in Figure 1(a) were kindly provided by Nippon
Shinykau Co., Ltd. (Kyoto, Japan). These RNA oligonu-
cleotides were synthesized as previously described [14]. To
anneal shRNAs, shRNAs suspended in water were incubated
for 5min at 95◦C in a heat block and then left until
the block reached 25◦C according to the manufacturer’s
protocol. Control (siGENOME Non-Targeting siRNA no. 2,
denoted as “ctrl”) and custom designed siRNAs for LMNA
were purchased from Dharmacon Research (Lafayette, CO,
USA). Negative control pre-miRNA (denoted “P.N.”) was
from Ambion (Austin, TX, USA).
2.2. Plasmid Construction. H u m a nA g o 2( h A g o 2 )c D N Aw a s
ampliﬁed by PCR using the primers 5 -GGATCCATG-
TACTCGGGAGCCGGC-3  and 5 -GCGGCCGCTCAA-
GCAAAGTACATGGTG-3  after reverse transcription from
total RNA isolated from HeLa cells and cloned into the
pCR-blunt vector (Invitrogen, Carlsbad, CA, USA). A
KpnIa n dNotI fragment containing a FLAG-tag coding
region in the pcDNA3FLAG vector (kindly gift from E.
Nishida, Kyoto University, Japan) was ligated with the KpnI
and NotI-digested expression vector pcDNA5FRT (Invit-
rogen), yielding the pcDNA5FLAG vector. A BamHIa n d
NotI fragment of hAgo2 cDNA in the pCR-Blunt vector
was ligated with BamHIa n dNotI-digested pcDNA5FLAG
vector, yielding the pcDNA5FLAG–hAgo2 plasmid. An
EcoRI site was introduced into the XbaIs i t eo ft h el u -
ciferase reporter vector pGL4.13 (Promega, Madison, WI,
USA) by ligation with the oligonucleotides 5 -CTAGAC-
TGAATTC-3  and 5 -CTAGGAATTCAGT-3 , yielding the
pGL4.13EcoRI vector. The oligonucleotides 5 -CTAGAG-
AAGGAGGAACTGGACTTCCAG-3  and 5 -AATTCTGGA-
AGTCCAGTTCCTCCTTCT-3  were annealed to form a
dsDNA fragment, which was ligated with XbaIa n dEcoRI-
digested pGL4.13EcoRI to produce the pGL4-LMNA plas-
mid. The identity of all constructs was conﬁrmed by DNA
sequencing.
2.3. Cell Culture and Transfection. A HEK293 line stably
expressing FLAG-hAgo2 was established by using the Flp-
In Expression System (Invitrogen) with the pcDNA5FLAG-
hAgo2 plasmid and Flp-In-293 Cell Line (Invitrogen)
according to the manufacturer’s protocol. HeLa cells and
HEK293-derivative cells were maintained in DMEM with
10% fetal bovine serum and antibiotics (100U/mL peni-
cillin and 100μg/mL streptomycin for both cell types, plus
100μg/mL Hygromycin B for HEK293-derivative cells). Syn-
thetic small RNAs were transfected by using X-tremeGENE
siRNA Transfection Reagent (Roche, Mannheim Germany).
Reporter plasmids were transfected by using FuGENE 6
Transfection Reagent (Roche). HeLa cells were plated in
24-well plates (3 × 104 cells/well) and in 12-well plates
(6 × 104 cells/well), and HEK293-derivative cells were
plated in 10cm dishes (2 × 106 cells/dish) 24 h before
transfection.
2.4. RNA Extraction and qRT-PCR Analysis. Total RNA
was isolated from cultured cells with an RNeasy mini
kit (QIAGEN, Hilden, Germany). To isolate RNA from
immunoprecipitated hAgo2 protein, cells were lysed in
20mM HEPES (pH 7.4), 150mM NaCl, 1mM MgCl2,1m M
EGTA, 1mM DTT, 1% EMPIGEN BB detergent (Sigma-
Aldrich, St. Louis, MO, USA), 40U/mL R Ribonuclease
Inhibitor (Takara Bio Inc., Shiga, Japan) and 1% Protease
Inhibitor Cocktail (Nacalai Tesque, Kyoto, Japan). FLAG-
hAgo2 was immunoprecipitated with anti-FLAG M2 agarose
beads (Sigma-Aldrich), and the beads were washed three
times with lysis buﬀer and then directly suspended in the
RNA extraction reagent ISOGEN (Nippon Gene Co., Ltd.,
Tokyo, Japan) to elute immunoprecipitated samples contain-
ingRNAs.RNAelutedinIsogenwasisolatedaccordingtothe
manufacturer’s protocol.
To analyze mRNA expression, a QuantiTect Reverse
Transcription Kit (QIAGEN) and a Power SYBR Green PCR
Master Mix (Applied Biosystems, Carlsbad, CA, USA) were
used. To quantify the amount of antisense and sense
strand in the RISC, a miScript PCR System (QIAGEN)
was used. The primers for PCR analysis were 5 -GGAAGT-
CCAGTTCCTCCTTC-3  for the LMNA antisense strand,
5 -GAAGGAGGAACTGGACTTCCA-3  for the LMNA sense
strand, 5 -GAAGGAGGCTGGACTTCCA-3  for the LMNA
sense strand with a deletion, and 5 -TAGCTTATCAGA-
CTGATGTTG-3  for miR-21; 5 -AGTCCATTCAGACAT
TGGGAG-3  and 5 -GTTGTAGATGAAGGTGAGCAG-3 
forIRF9; and5 -CAACCATGAGTACAAATGGTG-3  and5 -
CTAGTAGGTTGTGTATTCCCA-3  for IFIT1.
2.5. Immunoblotting and Reporter Analysis. For the immun-
oblotting assay, HeLa cells plated on 12-well plates were
transfected with 5pmol of RNA oligonucleotide. After 48h,
the cells were harvested by scraping them from culture
dishes into hot 1× S D Ss a m p l eb u ﬀer, and the lysates were
separated by SDS-PAGE and analyzed by immunoblotting.
The immunoblots were visualized and quantiﬁed by using
an LAS-3000 imaging system (Fujiﬁlm, Tokyo, Japan) and
normalized to the levels of β-actin. Anti-Lamin A/C rabbit
IgG (no. 2032) was purchased from Cell Signaling (Danvers,
MA, USA). Anti-Lamin A rabbit IgG (L1293) and β-actin
monoclonal mouse IgG (clone A-15) were from Sigma-
Aldrich.Journal of Nucleic Acids 3
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Figure 1: Design of pre-miRNA-based shRNAs and their RNAi
activity. (a) The set of four synthetic shRNAs containing a 21 or
24bp stem, either with or without a 2bp deletion of the 3  arm,
is represented. The underlined sequences are complementary to
the LMNA mRNA sequence. The lower cases are derived from
the human pre-miR-155 sequence. (b) The RNAi activity of these
shRNAs targeting LMNA was analyzed by immunoblotting. TF is
the abbreviation for transfection.
For the reporter assay, HeLa cells plated in 24-well plates
were transfected ﬁrst with RNA oligonucleotide (0.25, 1.25,
2.5pmol) 24h before harvesting and then with reporter
plasmid (100ng/well reporter luciferase plasmid, pGL4-
LMNA, and 25ng/well renilla luciferase vector, pGL4.73;
Promega) 30min later. The luciferase activity was measured
by using a dual-luciferase reporter assay system (Promega)
with a Lumat LB9507 luminometer (Berthold Technologies,
Bad Wildbad, Germany). As an internal control, renilla
luciferase activity was used. The data reported represent
the means and standard deviations of three independent
experiments.
2.6. Microarray Analysis. HeLa cells plated on 12-well plates
were transfected with 5pmol of RNA oligonucleotide, and
RNA was extracted 48h after transfection. 100ng of total
RNA was ampliﬁed and labeled by using an Ambion
WT Expression Kit (Ambion) according to the supplier’s
protocol. HG-U133 Plus 2.0 arrays (Aﬀymetrix, Santa Clara,
CA, USA) were hybridized with 11μg of labeled cRNA,
washed, stained, and scanned according to the protocol
described in the Aﬀymetrix GeneChip Expression Analysis
Manual. Aﬀymetrix data were extracted, normalized, and
summarized with the robust multiaverage (RMA) method
Expression Console.
3. Results
3.1. Design of Pre-miRNA-Based shRNAs. To assess the activ-
ity of synthetic shRNAs, we selected Lamin A/C (LMNA) as
an RNAi target because this gene has been widely used as a
positivecontrolinsiRNAexperiments.Previousreportshave
developed miR-155-based vectors for RNAi [15, 16]; thus,
we designed four shRNAs modeled on the pre-miRNA of
human miR-155 (Figure 1(a)). All of the designed shRNAs
had the same target site of the LMNA coding region but
slightly diﬀerent structures. The 17nt loop structure and the
2nt3   overhang were common parameters and are present
in human pre-miR-155. It is known that Dicer eﬃciently
cleaves dsRNA with a 2nt 3  overhang [11, 17] and that most
pre-miRNAs have a 2nt 3  overhang generated by Drosha
cleavage [18].TwoshRNAs(shRNAno.1andshRNAno.1b)
hada24bpstemlengthwithorwithoutaninternalbulge,the
other two (shRNA no. 2 and shRNA no. 2b) had a 21bp stem
length, generated by simply shortening the corresponding
24bp stem shRNA at the loop side. Unlike in a previous
report [11], the antisense strands were positioned 5  to the
loop. This position ensured that the antisense strand had a
ﬁxed 5  end, irrespective of the position of cleavage by Dicer.
The internal bulges in the stem region were introduced by
a 2nt deletion in the 3 -arm sequence mimic the structures
of pre-miRNAs. These shRNAs were tested for their ability
to silence the endogenous LMNA gene. HeLa cells were
transfected with each shRNA, and the expression of LMNA
protein was analyzed by immunoblotting. All four shRNAs
knocked down expression of LMNA with similar eﬃciency
(Figure 1(b)).
3.2. Potent RNAi Activity of Synthetic shRNA. Next, we
compared the activity of siRNAs and shRNAs, by synthe-
sizing siRNAs with same target sequence as the shRNAs.
Immunoblotting analysis showed that shRNA no. 2 and
shRNA no. 2b had RNAi activity comparable to that of the
corresponding siRNA (Figure 2(a)). When shRNA no. 1 and
shRNA no. 1b were used, essentially the same results were
obtained (data not shown).
To analyze the activity more quantitatively, a more
sensitive assay was conducted. We generated a luciferase
construct that contained a perfectly complementary target
site in its 3 -UTR and evaluated the reporter activity in cells
cotransfected with various concentrations of synthetic small
RNAs. All shRNAs, at all concentrations, were a 2- to 3-fold
more potent RNAi trigger than the corresponding siRNA
(Figure 2(b)). Importantly, even at the lowest concentration
(0.4nM), all shRNAs had silencing activity comparable to4 Journal of Nucleic Acids
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Figure 2: Comparison of the RNAi activity between synthetic shRNAs and their corresponding siRNAs. (a) The RNAi activity of siRNAs
and shRNAs was analyzed by immunoblotting. (b) The RNAi activity was monitored by a reporter assay system. The luciferase activity ratio
for the control siRNA (ctrl) was set as 1. (c), (d) The incorporation of transfected small RNA into the RISC was analyzed by qRT-PCR. Data
were normalized against the amount of miR-21 in the RISC. The amount of siRNA incorporated was set as 1. Each graph point in (b), (c),
and (d) represents the average (with s.d.) of three independent experiments.
that observed at their 10-fold higher concentration (4nM).
These results are coincident with previous reports [11, 19]
and indicate that synthetic shRNAs are more potent than
theircorrespondingsiRNAs.Inthisassay,wecouldnotdetect
signiﬁcant diﬀerences among the four shRNAs tested.
3.3. Eﬃciently Incorporation of Synthetic shRNAs into the
RISC. As previously discussed [11], we reasoned that the
more eﬀective RNAi achieved by shRNAs as compared
with siRNAs might reﬂect a diﬀerence in the eﬃciency of
their incorporation into the RISC. We therefore examined
the amount of antisense strands in the RISC generated
from transfected small RNAs. Two shRNAs (no. 1 and no.
1b) were transfected into HEK293 cells stably expressing
FLAG-tagged hAgo2 protein, which is a core component
of the RISC [20]. Processed RNAs loaded into the RISC
were isolated by coimmunoprecipitation with FLAG-tagged
hAgo2 protein. As expected, real-time quantitative RT-PCR
analysis revealed that the antisense strands derived from
s h R N A sw e r em o r ee ﬃciently incorporated into the RISC as
compared with those derived from the corresponding siRNA
(Figure 2(c)). Presumably, this eﬃcient incorporation into
the RISC underlies the highly potent silencing activity of
shRNAs.
Interestingly, introducing an internal bulge in the stem
increased the amount of antisense strands (compare no.
1b with no. 1 in Figure 2(c)). This might indicate that
the equilibrium between the sense and antisense strands
shifted towards antisense loading. We tested this equilibrium
shift by quantifying the amount of antisense strands in the
RISC. Indeed, introducing an internal bulge changed the
equilibrium toward antisense loading (Figure 2(d)).
3.4. Oﬀ-Target Eﬀects and Interferon Responses Induced by
Synthetic shRNAs in HeLa Cells. It is known that siRNAs can
cause oﬀ-target eﬀects [21]. Using microarray gene expres-
sion proﬁling, we compared the oﬀ-target eﬀects of our
synthetic small RNAs. From gene expression proﬁling, we
identiﬁed genes that showed a more than 2-fold decrease in
expression as compared with the control siRNA transfected
sample. A Venn diagram of these downregulated genes is
shown in Figure 3. As compared with siRNA, transfectionJournal of Nucleic Acids 5
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Figure 3: Oﬀ-target eﬀects induced by synthetic shRNAs. HeLa
cells were transfected with the indicated RNAs. After 48h, the
expression of about 20,000 protein-coding genes was analyzed by
microarray analysis. The overlap of genes that showed a more than
2-fold decrease in expression as compared with the control siRNA-
transfected sample is shown. The number in the overlapping region
of the Venn diagram represents shared genes. Note that the LMNA
gene is included in the commonly downregulated genes.
of shRNAs caused a broader downregulation of nontargeted
transcripts. This might be simply because of the eﬃcient
incorporation of synthetic shRNAs into the RISC and the
consequent higher potent RNAi activity (Figure 2(c)). We
noted that introducing a bulge decreased the number of oﬀ-
targetgenes(comparedno.2bwithno.2).Thisphenomenon
might reﬂect preferential incorporation of the antisense
strand into the RISC, as occurred when shRNAs with a bulge
were used (Figure 2(d)).
Next, we examined the expression of interferon-related
genes among the microarray data and found that IFIT1 [22]
andIRF9[23]wereinducedmorethan2-foldbytransfection
of shRNA no. 2. We further analyzed the expression of
thesetwogenesbyqRT-PCRanalysis(Figure 4).Transfection
of the siRNA upregulated IRF9 and IFIT1 expression by
approximately 1.5-fold; however, transfection of shRNAs
without a bulge caused slightly higher upregulation of these
genes. Again, shRNAs with a bulge improved interferon
responses. IFIT1 is known to be the mRNA that is most
strongly induced in response to dsRNAs [22]. Introducing
a bulge into the stem could circumvent this immune
activation.
4. Discussion
In this study, we demonstrated that synthetic pre-miRNA-
based shRNAs have more potent RNAi activity than their
corresponding siRNA and found that their antisense strands
a r em o r ee ﬃciently incorporated into the RISC. A previous
study also showed that synthetic shRNAs with a 27nt stem
and a 4nt artiﬁcial loop have a signiﬁcantly higher gene-
silencing activity than conventional 21nt siRNAs [11]. The
authors demonstrated that these small RNAs are subjected
to Dicer processing both in vitro and in vivo and speculated
that siRNA duplexes generated by Dicer are eﬃciently loaded
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Figure 4: Interferon responses induced by synthetic shRNAs. HeLa
cells were transfected with the indicated RNAs. After 48h, the
expression of two interferon-regulated genes IFIT1 and IRF9 was
analyzed by qRT-PCR.
into the RISC. In a study using DNA vector-based shRNAs,
two types of shRNA construct modeled on pre-miRNA
and pri-miRNA transcripts were examined [24]. The results
indicated that RNAi triggers that enter the RNAi pathway
by a more natural route yield more eﬀective silencing
[25]. Here we demonstrated the eﬃcient incorporation of
shRNAs into the RISC, and our results are highly consistent
with those of previous studies. Furthermore, introducing
a bulge enhanced incorporation into the RISC and shifted
the equilibrium toward antisense loading (Figures 2(c) and
2(d)). However, we did not observe a signiﬁcant diﬀerence
in RNAi activity among the synthetic shRNAs in our
assay (Figure 2(b)) ,p r o b a b l yb e c a u s et h e yw e r ea l lc l o s et o
saturation.
There are contradictory reports about the eﬀects of stem
length on RNAi activity. Some reports have shown that
shRNAs with a 19nt stem and a 9 or 10nt loop have
higher RNAi activity than shRNAs with longer stem [12, 26,
27]. This type of shRNA is widely used as a vector-based
shRNA [28]. Interestingly, shRNAs with a 19nt stem are not
Dicer substrates; however, these shRNAs are thought to be
incorporated into the RISC after bypassing Dicer processing
[11]. Although we reasoned that the development of shRNAs
based on naturally found structures is a promising approach,
we should also examine and evaluate this type of shRNA.
Unlike previously used shRNAs [11], our designed
shRNAs have a shorter stem length (21 or 24nt) and the loop
derived from a pre-miRNA and are therefore expected to be
less toxic. However, we observed that interferon responses
were induced more strongly by shRNAs than by their
corresponding siRNA. Interestingly, introducing a bulge also6 Journal of Nucleic Acids
reduced interferon responses. These observations, albeit of a
few examples, indicate that introducing a bulge has potential
for improving the performance of shRNAs. Further exam-
ination of the position and structure of bulges is required.
Chemical modiﬁcations of siRNAs have been extensively
studied to increase stability, promote eﬃcacy, minimize oﬀ-
target eﬀects, and reduce innate immune responses [5, 21].
Such modiﬁcations can be easily incorporated in synthetic
shRNAs to improve siRNA stability and biological activity,
similar to synthetic siRNAs. These are issues to be addressed
in the future.
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